Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is utilizing AI and machine learning for drug discovery, specializing in rare diseases and oncology. Recent advancements led to a 7% stock surge in September 2025, including a $12.5 million payment to Rallybio for the development of REV102. The company’s pipeline features six lead candidates across oncology and rare disease therapies, with ongoing clinical trial progress and collaborations with MIT, Tempus, and HealthVerity.

Read more at Yahoo Finance: Recursion Pharmaceuticals, Inc. (RXRX) Secures $12.5M Milestone From Rallybio as REV102 Advances